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Hepatocellular carcinoma (HCC) is the second most 
common cause of cancer-related death worldwide [1], 
generally arising on the background of chronic liver 
diseases such as chronic viral hepatitis, alcohol-induced 
liver injury, or fatty liver disease. So far, classification 
proposals for HCC based on molecular markers are not 
yet routinely applied in surgical pathology or clinical 
management of HCC patients. This stands in contrast to 
the classification of hepatocellular adenoma (HCA), 
which has been included in the latest WHO 
classification [2], and is the basis for a stratified 
management of HCA patients. 
Phenotypic intratumor heterogeneity in HCC with 
respect to morphology and differentiation grades within 
the same tumor is a well-known phenomenon to 
surgical pathologists. So far, genetic heterogeneity and 
the heterogeneity of biomarker expression in the 
surgical HCC specimens have not been systematically 
analyzed. However, to improve clinico-pathological 
classification systems and for the stratification of 
targeted therapies, it seems crucial to comprehensively 
characterize intratumor heterogeneity. 
In a systematic analysis of 23 treatment-naïve unifocal 
HCC, we investigated individual tumors for 
morphologic, immunohistochemical and genetic 
intratumor heterogeneity as well as the association of 
these three features [3]. We found morphologic hetero-
geneity in 87% of the tumors. Immunohistochemical 
heterogeneity with respect to five markers (CK7, CD44, 
AFP, EpCAM and glutamine synthethase) was present 
in 39% of cases and was always accompanied by 
morphologic heterogeneity. Clonal, i.e. genetic 
diversification was determined by sequencing the two 
most important HCC driver genes (TP53 and CTNNB1). 
Combining Sanger sequencing with deep sequencing 
techniques facilitated the discovery of low frequency 
mutations and mitigated the effect of wild-type 
contamination. A mean of 7 regions per tumor was 
sequenced (120 areas in total), and genetic intratumor 
heterogeneity was found in 22% of cases. Thus, already 
analysis of the two main HCC driver genes clearly 
revealed that mutations are not homogeneously present 
in all regions of an individual tumor. This was found 
especially for CTNNB1 mutations, but also for TP53 
mutations. The thorough dissection of morphologic, 
immunohistochemical  and genomic  intratumor  hetero- 
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geneity in our study illustrates that the primary co-
existence of different growth patterns can be associated 
with divers biomarker expression and TP53 or CTNNB1 
gene mutations among wild type tumor cells. Somatic 
mutations of various other genes are described in liver 
cancer, e.g. AXIN1 (WNT signaling), ARID and MLL 
genes (epigenetic modifiers), CDKN2A and IRF2 (cell 
cycle regulators interrelated with TP53) or TERT 
promoter mutations [4] . Although not comprehensively 
analyzed so far, it can be expected that the picture of 
subclonality within single liver lesions is even more 
complex. Tracking the expansion of certain tumor 
clones might also elucidate the development of 
multifocal liver cancer or disease progression favoring 
intra- and extrahepatic metastasis. 
Intratumor heterogeneity has major implications for 
diagnosis and therapy of many solid cancers, indicating 
that a single tumor biopsy might not provide sufficient 
informative value regarding the molecular 
characteristics of the whole tumor. Primary renal cell 
cancer, as has been shown by Gerlinger et al. [5], 
displays common and private mutations throughout 
different, grossly demarcated tumor regions. Intratumor 
heterogeneity also limits the informative value of the 
widely used tissue microarray technique for studies on 
novel prognostic or predictive biomarkers.  
The histopathologic and molecular classification of a 
tumor, often determined by the mutational status of a 
certain target, has therapeutic implications, e.g. in 
colorectal cancer (EGFR) or gastrointestinal stroma 
tumors (c-KIT). In the era of targeted therapies, 
intratumor heterogeneity is a major challenge to 
successful cancer therapy since it may result in primary 
resistance or early evasion of treatment to 
chemotherapeutic or molecular targeted substances. In 
melanoma, resistant tumor clones tend to evade 
chemotherapies and overgrow due to a forced selection 
process as well as an adaption process during tumor 
evolution. Therapy-induced inflammatory processes 
result not only in phenotypic plasticity of the tumor and 
its genomic landscape, but also alter the composition of 
tumor-associated immune cells. This  recomposition of 
the microenviroment can contribute to cancer evolution 
and therapy resistance [6]. 
In conclusion, determining the degree of intratumor 
heterogeneity might be seen as a biomarker by itself and 
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have prognostic value for disease progression [7]. With 
the high-throughput techniques widely available now, 
we envision the systematic investigation of intratumor 
heterogeneity in different types of cancer in order to 
pinpoint its clinical relevance. We expect that 
intratumor tumor heterogeneity with clinical relevance 
for molecular targeted therapy approaches will be 
present probably not in all, but in many tumor entities.  
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Figure  1.  Implications  of  HCC  intratumor  heterogeneity  for  tumor  classification  and  targeted
therapy. A biopsy taken from tumor area 2 does not necessarily represent the whole tumor. This
may  result  in  a  short  falling  tumor  classification  as  type  B,  and  potentially  in  an  incomplete
therapy response due to sensitivity of only one tumor subclone (mutation B, biomarker B‘, pink). 
